Purpose: To compare various characteristics of Xalatan â and five generic latanoprost ophthalmic solutions. Methods: Drop size, volume, pH values, buffer capacity, viscosity, hardness of bottles and costs were determined. Drop sizes were measured in triplicates by micropipettes, and the number of drops counted in three separate bottles of each generic product was determined. pH values were measured in triplicates by a calibrated pH meter. Buffer capacity was exploited by titrating known quantities of strong base into 2.5 ml of each brand and interpolated to neutral pH. Kinematic viscosity was determined by linear regression of timed gravity flow from a vertical syringe through a 21-G cannula. The hardness of the bottles was evaluated by gradually increasing tension on a hook placed around each bottle until a drop was expelled reading the tension on an attached spring scale. Results: Drop sizes and the number of drops in the bottles varied significantly between the generic drugs. The control value of pH in the brand version (Xalatan â ) was markedly lower compared to the generic latanoprost products. Titration of Xalatan â to neutrality required substantially more NaOH compared to the generic latanoprost products. Finally, the viscosity revealed a significant variability between brands. Remarkable differences were found in bottle shapes, bottle hardness and costs of the latanoprost generics. Conclusion: Generic latanoprost eye drops should not be considered identical to the original brand version as regards to drop size, volumes, pH values, buffer capacity, viscosity, hardness of bottles and costs. It is likely that these issues affect compliance and intraocular pressure (IOP)-lowering effect. Therefore, re-evaluation of the requirements for introducing generic eye drops seems reasonable.
Introduction
Generic eye drops are becoming a major part of treatment for glaucoma with the assumption that generics are exact copies of the original product.
Without doubt, they can produce cost savings for both patients and the healthcare system. However, even though generic drugs have the same active ingredients, they may differ with respect to inactive ingredients such as the adjuvant solution (Cantor 1997; Chambers 2012; Zore et al. 2013 ). This may affect factors such as pH, viscosity and buffer capacity and in turn pharmacokinetics, bioavailability and tolerability (Brechue & Maren 1993; Cantor 1997) . Moreover, no regulations concerning bottle material, shape and colours exist. As patients with glaucoma generally are elderly, a great proportion will suffer from rheumatic diseases and hence be dependent on manageable bottles. In addition, change in colour and shape may confuse patients and thereby influence their adherence. Over all, it is questionable whether the lack of requirements before introduction of new copy products is short-sighted.
In 2011, the patent on the most common drug against glaucoma, Xalatan Ò (Pfizer, Ballerup, Denmark), expired (Stein et al. 2008; Kolko et al. 2015) . Since then, a number of copy products have been released. Few studies have compared the clinical effect of Xalatan Ò to its generic products, named latanoprost ophthalmic solutions (Narayanaswamy et al. 2007; Egan et al. 2014; Golan et al. 2015) . In general, concerns have been raised on the clinical effect although no longitudinal studies have been performed. In turn, insight into glaucoma progression differences in patients treated with generic equivalents still remains to be exploited. Obviously, comparative studies are costly and perhaps strict regulations with requirement for such would not be beneficial. However, more readily requirements could be statutory before acceptance of copy products. In turn, simple properties such as drop size, volume, pH, buffer capacity, viscosity, bottle colour and bottle design constitute features that are more easily assessed. A recent study evaluated the stability of pH in different generic formulations and found significant variability (Velpandian et al. 2015) . It is obvious that such variation will affect adherence and possibly the effect of the given medication. Drop size, volume, buffer capacity and viscosity are other factors that will influence the amount of drug that enters the surface of the eye. Moreover, increased tear volume and drainage through the nasolacrimal system will dilute the drug (Ariturk et al. 1996) , and low retention time will decrease the penetration of the cornea and conjunctiva (Ahmed et al. 1987) . Finally, bottle hardness affects the delivery of the drug reaching the eye surface (Moore et al. 2016) . In spite of an increasing number of generic eye drops, only limited studies have evaluated these factors in the increasing range of generics. In this study, we evaluated five different latanoprost generics and compared them to the brand name, Xalatan
Ò

Materials and Methods
Five generic brands of latanoprost ophthalmic solutions available in Denmark from Pfizer, Actavis, Sandoz, Stada (Herlev, Denmark) and Teva were included and compared to Xalatan Ò The drop size of the contents was measured in triplicates by micropipettes, and the number of drops counted in three separate bottles of each product. Measurements of pH values were performed by a calibrated pH meter. Three independent measurements were performed in three separate bottles. The measurements were repeated to confirm the results.
The hardness of the bottles was evaluated with a spring scale attached to a hook that conformed to bottle curvature. The hook was carefully centred on each bottle perpendicular to the axis. Tension was gradually increased, and the levels for release of three successive drops in free air were recorded. Subsequently, total tension was released and the evaluations were repeated three times on three independent bottles for each generic.
Titrations of 2.5 ml of each brand were performed by adding known quantities of 1 M NaOH and interpolated to neutral pH = 7.4 by a nonlinear logistic regression fit using Microsoft Excel Solver (Lyngby, Denmark).
Kinematic viscosity was determined by linear regression of split-time recordings of successive 0.1 ml of gravity outflow from a vertical 1-ml syringe through a 21-G cannula into a water bath (see Appendix s1).
Statistical analysis
All statistical analyses were performed in GraphPad Prism 6.0 software (GraphPad Software, La Jolla, CA, USA), and p-values less than 0.05 were considered significant. All data are expressed as means AE SD, and differences between conditions were analysed using ordinary one-way analysis of variance (ANOVA) followed by Tukey's multiple variance comparisons test.
Results
Drop sizes and volume varied significantly between the brand version (Xalatan Ò ) and the generic latanoprost products in the range of 40-46 ll (Fig. 1) . The number of drops in each generic bottle varied between 92 and 111 drops (Fig. 1A) , and the drop volume ranged between 40 and 46 ll (Fig. 1B) .
The control value of pH in the brand version (Xalatan Ò ) was 5.99 AE 0.01, whereas the generic latanoprost products had significantly higher values in the range 6.70-6.82 (Fig. 1C) . Furthermore, pH differences were found inbetween the latanoprost generic drugs (Table 1) .
Titration of 2.5 ml Xalatan Ò to neutrality required 70.4 AE 0.4 nmol NaOH compared to the generic latanoprost products, which required within the range 28.1-33.7 nmol NaOH (Fig. 1D) .
The viscosity in one of the generic products latanoprost (Stada) revealed a significant higher value compared to the other tested generics (Fig. 2A) . Significant viscosity differences were furthermore observed between latanoprost Actavis and latanoprost Teva as well as between latanoprost Pfizer and latanoprost Teva (Fig. 2A) .
The average force to release three subsequent drops varied significantly between Xalatan Ò and the generic latanoprost drugs (Fig. 3B, Table 2 ). Xalatan Ò required the least pressure to the mid-bottle to release a drop. Over all, differences were found for hardness in the range of 1.8-2.7 kg for release of the first drop (Fig. 3B, Table 2 ). Successive drops required more tension: +22 AE 7% and +37 AE 13% for release of the second and third drops, respectively, whereupon the Triplicate mean values of pH in latanoprost generics AESD (n = 6, p < 0.0001, ordinary one-way ANOVA followed by Tukey's multiple comparisons analysis is outlined in Table 1 ). (D) Amount of 1M NaOH required for titration of 2.5 ml drug to neutrality. Mean values are shown AESD (n = 3, ****p < 0.0001, ordinary one-way ANOVA). Multiple comparisons analysis shows no significant differences inbetween the generic drugs. *p < 0.05, **p < 0.001, ***p < 0.0001. cycle was repeated until the bottle was empty.
The price of the generics at the time of evaluation revealed extensive variations with Xalatan Ò about 10 times more expensive than its generic drugs (Fig. 3A) .Finally, remarkable differences were found in the shape of latanoprost generic bottles and colours (Fig. 3B) .
Discussion
According to the Danish Generic medicines industry association (IGL), pharmaceutical companies are entitled to obtain a patent in order to obtain new and better medications. The current length of a patent is 20 years in total. In turn, within those 20 years, a potential new medication will have to pass various trials and regulations. In addition, an innovative medical industry will obviously have more pipelines of which only the fewest will lead to final products. This matter leads to the question of how long a patent ideally should last, and more importantly, what the requirements for the introduction of generics should be? Obviously, the current health sector is expensive and access to lower cost medication in isolated terms is an advantage. Yet, the population expects equal quality and effect of generics. The question is whether the current regulations are neglecting factors that might lead to uncertainty of the efficacy of generic compounds. According to the European Medicines Agency (EMA), the introduction of generic drugs does not require preclinical or clinical studies as long as the qualitative and quantitative composition in the active substance is identical to the original brand. Thus, the requirements from EMA of a generic drug consist of an identical pharmaceutical form and a similar bioequivalence. Due to the rather lenient requirements, more studies have compared generics to branded drugs and shown different clinical efficacy (Rosenbaum et al. 1994; Reiffel 2000; Burkhardt et al. 2004; Van Ameringen et al. 2007; Desmarais et al. 2011; Fitzgerald & Jacobson 2011) . While concern has been more frequently raised regarding substitution of generic drugs for branded systemic drugs, specific additional issues arise in the case of ophthalmic eye drops. Although generic ophthalmic drugs have the same active ingredients as branded drugs, the eye drops may differ with respect to inactive ingredients. Examples of inactive ingredients include pH, buffer capacity and thickening agents. All these factors may affect the pharmacokinetics and thus result in different efficacy. Moreover, there exist no clear regulations on the drop size and the design of the container. In this matter, it is clear that a higher volume may differ in efficacy compared to lower volume applied. The hardness of the bottle and thereby the needed force to release eye drops would tentatively affect adherence. In the present study, we exploited the most used eye drop for glaucoma, Xalatan Ò , and its five available generic compounds in Denmark. We identified significant differences such as drop sizes, volume, pH, viscosity, buffer capacity, as well as significant variations in hardness and shapes of the bottles. Even though the present study does not present evidence on the efficacy of the exploited generics, it is clear that we report critical differences. Hence, previous studies have shown that corneal penetration depends on the viscosity (Baudouin et al. 2010) . Moreover, pH changes will highly affect the corneal À0.14 **** Differences (SD = 0.0167) are shown between the evaluated latanoprost generics. *p < 0.05, **p < 0.001, ****p < 0.00001, ns = none significant. Triplicate mean values AE SD are shown (n = 3, ordinary one-way ANOVA followed by Tukey's multiple comparison test). Stada was significantly different than all other generics. (B) Average of force used for expulsion of successive drops AESD is shown (n = 10 measurements in three bottles of each generica) for drops 1, 2 and 3, respectively. Ordinary one-way ANOVA followed by Tukey's multiple comparison test was performed. Statistics are shown in Table 2 . (C) A spring scale attached to a hook that conforms with bottle curvature. The hook is carefully centred on the bottle perpendicular to the axis. *p < 0.05, **p < 0.001, ***p < 0.0001. surface and penetrance (Gonnering et al. 1979; Malhotra & Majumdar 2001) . Over all, the present study identifies critical factors affecting bioavailability in the exploited latanoprost generics. Thus, our study raises obvious concerns of the current regulations and requirements for introduction of generic eye drops.
Conclusion
The idea that generics are equal to branded medications when the active ingredients are the same is not necessarily true. Many factors that affect the efficacy of a topical medication are independent of the active ingredients such as drop size, pH, thickening agents, buffer capacity, bottle material, bottle shape and size, and cap colour. The present study identifies differences among latanoprost generics such as different drop size, pH values, viscosity and buffer capacities. Moreover, the bottle design and hardness varies significantly, thereby leading to critical variations in the handling of the generics. Finally, the price variations between the brand version and the generics showed striking difference. In the current regulations, no requirements for efficacy testing are required and as such, it is currently impossible to know whether treatment with generic latanoprost products provide identical pressure-lowering effects. Overall, generic eye drops should not be considered identical to the original brand version as regards comfort and compliance. Therefore, re-evaluation of the requirements for introducing generic drugs seems reasonable.
